Effect of thalidomide on signal transduction pathways and secondary damage in experimental spinal cord trauma

Shock

Volumn 30, Issue 3, 2008, Pages 231-240

  Genovese, Tiziana ^a   Mazzon, Emanuela ^a   Esposito, Emanuela ^a,b   Di Paola, Rosanna ^a   Caminiti, Rocco ^c   Meli, Rosaria ^b   Bramanti, Placido ^a   Cuzzocrea, Salvatore ^a,c  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Apoptosis; Neutrophil infiltration; SCI; Thalidomide; TNF

Indexed keywords

3 NITROTYROSINE; CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MYELOPEROXIDASE; PROTEIN BAX; PROTEIN BCL 2; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANEURYSM CLIP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DURA MATER; EDEMA; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HISTOPATHOLOGY; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; LAMINECTOMY; LIMB; LIPID PEROXIDATION; MALE; MEDIATOR; MOUSE; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; SCORING SYSTEM; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; THORACIC SPINE; TISSUE INJURY;

ANIMALS; APOPTOSIS; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; LIPID PEROXIDATION; MALE; MICE; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASE; SIGNAL TRANSDUCTION; SPINAL CORD; SPINAL CORD INJURIES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 52649116978     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318162d290     Document Type: Article

References (39)

1. Bartholdi D, Schwab ME: Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res 672:177-186, 1995.
2. Harrington JF, Messier AA, Levine A, Szmydynger-Chodobska J, Chodobski A: Shedding of tumor necrosis factor type 1 receptor after experimental spinal cord injury. J Neurotrauma 22:919-928, 2005.
3. Hayashi M, Ueyama T, Nemoto K, Tamaki T, Senba E: Sequential mRNA expression for immediate early genes, cytokines, and neurotrophins in spinal cord injury. J Neurotrauma 17:203-218, 2000.
4. Kapadia S, Torre-Amione G, Yokoyama T, Mann DL: Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol 268:H517-H525, 1995.
5. Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Bramanti P, Cuzzocrea S: Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther 316:1006-1016, 2006.
6. McBride W: Health of thalidomide victims and their progeny. Lancet 363:169, 2004.
7. Eriksson T, Bjorkman S, Hoglund P: Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57:365-376, 2001.
8. Meierhofcr C, Dunzendorfer S. Wiedermann CJ: Theoretical basis for the activity of thalidomide. BioDrugs 15:681-703, 2001.
9. Sampaio EP, Sarno EN, Galilly R. Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699-703, 1991.
10. Laffitte E. Revuz J: Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf 3:47-56, 2004.
11. Yasui K, Kobayashi N, Yamazaki T, Agematsu K: Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des 11:395-401, 2005.
12. Holm AL, Bowers KE, McMeekin TO, Gaspari AA: Chronic cutaneous lupus erythematosus treated with thalidomide. Arch Dermatol 129:1548-1550, 1993.
13. Vogelsang GB, Farmer ER, Hess AD, Altamome V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, et al.: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055-1058, 1992.
14. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O: Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 16:158-163, 1989.
15. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A. Yurdakul S, Zwingenberger K, Yazici H: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443-450, 1998.
16. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanaucr SB: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117:1271-1277, 1999.
17. Lee CJ, Kim KW, Lee HM, Nahm FS, Lim YJ, Park JH, Kim CS: The effect of thalidomide on spinal cord ischemia/reperfusion injury in a rabbit model. Spinal Cord 45:149-157, 2007.
18. Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:157-167, 1985.
19. Shea TB: Technical report. An inexpensive densitometric analysis system using a Macintosh computer and a desktop scanner. Biotechniques 16: 1126-1128, 1994.
20. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358, 1979.
21. Joshi M, Fehlings MG: Development and characterization of a novel, graded model of clip compressive spinal cord injury in the mouse: Part 1. Clip design, behavioral outcomes, and histopathology. J Neurotrauma 19:75-190. 2002.
22. Joshi M, Pehlings MG: Development and characterization of a novel, graded model of clip compressive spinal curd injury in the mouse: Part 2. Quantitative neuroanatomical assessment and analysis of the relationships between axonal tracts, residual tissue, ami locomotor recovery. J Seurotrauma 19:191-203, 2002.
23. Popovich PG, Jones TB: Manipulating neuroinflammatory reactions in the injured spinal cord: back to basics. Trends Pharmacol Sci 24:13-17, 2003.
24. McTigue DM, Popovich PG, Jakeman LB, Stokes BT: Strategies for spinal cord injury repair. Prog Brain Res 128:3-8, 2000.
25. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E: The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatal 25:964-969, 1998.
26. Ahn YH, Lee G, Kang SK: Molecular insights of the injured lesions of rat spinal cords: inflammation, apoptosis. and cell survival. Biochem Biophys Res Commun 348:560-570, 2006.
27. Verma IM: Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann Rheum Dis 63(suppl 2):ii57-ii61, 2004.
28. Ruetten H. Thiemermann C: Effect of calpain inhibitor I. an inhibitor of the proteolysis of 1 kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol 121:695-704, 1997.
29. Jin SH, Kim TI, Han DS, Shin SK, Kim WH: Thalidomide suppresses the interleukin 1 beta-induced NFkappaB signaling pathway in colon cancer cells. Ann N Y Acad Sci 973:414-418, 2002.
30. Streil WJ, Semple-Rowland SL, Hurley SD, Miller RC, Popovich PG, Stokes BT: Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliusis. Exp Neurol 152:74-87, 1998.
31. Perkins DJ. St Clair EW, Misukonis MA, Weinberg JB: Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum 41:2205-2210, 1998.
32. Xu J, Kim GM, Chen S, Yan P, Ahmed SH, Ku G, Beckman JS, Xu XM, Hsu CY: iNOS and nitrotyrosine expression after spinal cord injury. J Neurotrauma 18:523-532, 2001.
33. Beckman JS: Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 9:836-844, 1996.
34. Endoh M, Maiese K, Wagner J: Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res 651:92-100, 1994.
35. Merrill JE, Ignarro LJ, Sherman MP, Mclinck J, Lane TE: Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 151:2132-2141, 1993.
36. Muzio M, Salvesen GS, Dixit VM: FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem 272:2952-2956, 1997.
37. Hisahara S, Shoji S, Okano H, Miura M: ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem 69:10-20, 1997.
38. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan Gl, Guild BC: Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374:733-736, 1995.
39. Nesic-Taylor O, Cittelly D. Ye Z, Xu GY. Unabia G, Lee JC, Svrakic NM, Liu XH, Youle RJ, Wood TG, et al.: Exogenous Bcl-xL fusion protein spares neurons after spinal cord injury. J Neurosci Res 79:628-637, 2005.